Stuart Titus
states:
"MJNA and the new leadership has recognized the value of the wonderful leadership that the AXIM team provides. Alongside the new relationship with CanChew Biotechnologies and their patent on chewing gum and cannabinoids - the promise for significant IP, significant new products and pharmaceutical development exists. MJNA salutes and supports the team led by
Dr. Anastassov
in their clinical efforts and believes their delivery method for cannabinoids may provide a well-accepted and therapeutically improved delivery for cannabinoid-based pain medication, via the MedChew clinical trials ongoing in
Europe
. Recent
FDA
warnings have shown additional potential side effects from traditional NSAID medications - thus the MedChew trials are quite timely and well-needed. In fact, the
FDA
The Netherlands
asked AXIM to specifically carry on these well-needed trials. Although MJNA and our team are not directly involved with these efforts, nonetheless, we strongly support any and all studies for safety and efficacy that the AXIM team is involved with. At MJNA we feel that further research will show the full potential for cannabinoids to the world of medicine - just as many anecdotal stories have shown with the botanical formulations available today. "
About
:
AXIM Biotechnologies
(OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com. FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of
Section
27A of the Securities Act of 1933 and
Section
21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of
Axim Biotechnologies, Inc.
to be materially different from the statements made herein. LEGAL DISCLOSURE
AXIM Biotechnologies
does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products. North American Address:


AXIM Biot : chnologies Clarifies Relationship With Medical Marijuana, Inc. and CanChew Biotechnologies, LLC

AXIM Biotechnologies Clarifies Relationship With Medical Marijuana, Inc. and CanChew Biotechnologies, LLC
    
July 31, 2015 20:00
ET | Source: AXIM Biotechnologies, Inc
NEW YORK, July 31, 2015 (GLOBE NEWSWIRE) -- A statement from AXIM Biotechnologies (OTC:AXIM), an innovative biotechnology company:
"We have received numerous telephone calls from the public leading us to believe there is general confusion relating to our relationship with Medical Marijuana, Inc. and CanChew Biotechnologies, LLC," says Dr. George Anastassov, President of AXIM Biotechnologies, Inc. "AXIM's business focus has been and continues to be on being an innovative biotechnology company working on solutions for the treatment of pain, spasticity, anxiety and other medical disorders and symptoms with the application of cannabinoid-based products as well as focusing on research, development and production of pharmaceutical, nutraceutical, oral health and cosmetic products as well as procurement of genetically and nano-controlled active ingredients. "
Medical Marijuana, Inc. (MJNA) is the first publicly held company vested in the medical marijuana and industrial hemp markets. MJNA is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries. MJNA is a major shareholder of AXIM, holding approximately 47% of our common stock, but neither it nor any of its affiliates participate in the management or operations of AXIM in any manner. Sanammad Foundation, a Netherlands based company, also owns 47% of our common stock. Sanammad Foundation's three members, Dr. George Anastassov, Dr. Philip A. Van Damme and Dr. Lekhram Changoer, are AXIM's three directors and manage AXIM's daily operations. CanChew Biotechnologies, LLC, holds a US patent for the production of unique time-release cannabinoid-infused chewing gum. On May 1, 2015, AXIM entered into a 50 year, worldwide, exclusive licensing agreement with CanChew wherein AXIM acquired the intellectual property rights underlying the patent to allow AXIM to produce CanChew Plus™ a unique time-release industrial hemp oil derived CBD (cannabidiol)-infused chewing gum. Medical Marijuana, Inc. financed CanChew's initial operations and owns 50% of CanChew's membership interest. However, in accordance with the company's operating agreement, Medical Marijuana, Inc. does not manage or control CanChew's operations. Sanammad Foundation owns the remaining 50% membership interest of CanChew and manages daily operations. A statement from Medical Marijuana, Inc. CEO Stuart Titus states:
"MJNA and the new leadership has recognized the value of the wonderful leadership that the AXIM team provides. Alongside the new relationship with CanChew Biotechnologies and their patent on chewing gum and cannabinoids - the promise for significant IP, significant new products and pharmaceutical development exists. MJNA salutes and supports the team led by Dr. Anastassov in their clinical efforts and believes their delivery method for cannabinoids may provide a well-accepted and therapeutically improved delivery for cannabinoid-based pain medication, via the MedChew clinical trials ongoing in Europe. Recent FDA warnings have shown additional potential side effects from traditional NSAID medications - thus the MedChew trials are quite timely and well-needed. In fact, the FDA equivalent in The Netherlands asked AXIM to specifically carry on these well-needed trials. Although MJNA and our team are not directly involved with these efforts, nonetheless, we strongly support any and all studies for safety and efficacy that the AXIM team is involved with. At MJNA we feel that further research will show the full potential for cannabinoids to the world of medicine - just as many anecdotal stories have shown with the botanical formulations available today. "
About AXIM Biotechnologies:
AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com . FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE
AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products. North American Address:18 East 50th Street, 5 FloorNew York, NY 10022+1 844 294 6246European Address:Boelewerf 32, Unit 32987 VD Ridderkerk, The Netherlands+31 10 8209 227
Related Articles


AXIM Biotechnologies Clarifies Relationship With Medical Marijuana, Inc. and CanChew Biotechnologies, LLC

Dr. Oz The Good Life Magazine
For more information on CanChew® visit www.CanChewGum.com . AXIM Biotechnologies, Inc. (OTC:AXIM) is the exclusive license recipient to the world's first patented cannabinoid release gum. Dr. George E. Anastassov was a conference presenter on cannabinoid delivery methods at the Chicago Cannabis Conference. For more information, visit www.AXIMBiotech.com . About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company's website at: www.MedicalMarijuanaInc.com
About CanChew Biotechnologies, LLC
CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of cannabinoid medical products as well as food and nutraceutical products for general well-being. The company is focused on the R&D and execution of their clinical development plan and potential out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of conditions like pain, nausea and vomiting, anorexia, spasticity and various other medical issues. For more information on the company, visit CanChewGum.com . FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE
Medical Marijuana Inc. and HempMeds do not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil. For further information, please contact:Public Relations contact:Andrew HardSpokespersonCMW MediaP. 858-380-5478Corporate contact:Medical Marijuana, Inc.Toll Free: 888-OTC-MJNA (888-682-6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc Investor Relations:GH Investment Advisors550 West "C" Street, Ste. 2040San Diego, CA 92101Nick MassalasOffice:  (858) 264-6500Toll Free: (877) 964-6463
Related Articles
other press releases by Medical Marijuana Inc


Medical Marijuana, Inc.’s CanChew -- Patented Cannabis Gum -- Featured in ABC, NBC, CBS, Yahoo! News and More From Chicago Cannabis Convention

Photo Release -- Patent for World's First Cannabinoid Release Gum Awarded to Medical Marijuana, Inc.'s Joint Venture Partner -- CanChew Biotechnologies, LLC
One Innovative Cannabinoid Release Gum, Two R&D Markets: Consumer & Pharmaceutical
    
ET | Source: Medical Marijuana Inc
photo-release
Patented, Award-Winning CanChew Hemp Cannabinoid ReleaseGum
SAN DIEGO, May 27, 2015 (GLOBE NEWSWIRE) -- Medical Marijuana, Inc. (OTC Pink:MJNA), a leading industrial hemp industry innovator, is proud to announce that its joint venture partner, CanChew Biotechnologies, LLC ( CanChew ®), was awarded the U.S. Patent for Chewing Gum Compositions Comprising Cannabinoids (United States Patent 9023322 ). The patent was also applied for in Europe, Canada Mexico, Japan, China, India, Australia, Singapore, among others. A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=33270
In April 2012, the joint venture by Sanammad Foundation and Medical Marijuana, Inc. resulted in MJNA acquiring a 50% stake in the new company and creation of CanChew Biotechnologies . CanChew Biotechnologies created a wholly-owned subsidiary, CannaGum Marketing Group, for the purpose of marketing and selling CanChew® gum. "Announcing the world's first patented cannabinoid chewing gum is a major victory for the industrial hemp and cannabis industry," states Stuart Titus, PhD and CEO of Medical Marijuana, Inc. "We are thrilled that after many years of hard work, our team has successfully received a U.S. Patent for Chewing Gum Compositions Comprising Cannabinoids. For consumers, chewing gum is well accepted as an easy, convenient way to get nutraceutical health and wellness benefits. Since chewing gum is a food, potentially this may be considered a functional food with the hemp oil containing significant omega essential fatty acids. "
The Nutritional Business Journal identifies the $300 billion global nutrition industry as including all dietary supplements, natural & organic foods and beverages, functional foods and beverages, and natural & organic personal care & household products. CanChew ® is a unique, patented, award-winning cannabinoid release chewing gum that is distinctly different than any other brand of gum on the market today. Features listed on the CanChew ® website include:
Non-habit forming
Available in all 50 states
Great-tasting mint gum has no artificial sweeteners or preservatives
Non-GMO, gluten free, vegan and kosher
AXIM Biotechnologies, Inc. (OTC:AXIM) is the exclusive license recipient to the world's first patented cannabinoid release gum and is set to launch CanChew® Plus, an organic and functional food product, in the third quarter of 2015. Meanwhile, the study – Medicine Use and Shifting Costs of Healthcare: A Review of the Use of Medicines in the United States in 2013 – found that total dollars spent on medications in the U.S. reached $329.2 billion. Dr. Titus continues, "Further on the medical side, the U.S. Patent 9023322  will allow for CanChew ®, with its relationship with AXIM Biotechnologies , Inc. to develop their MedChew RX™ plans further. Initially in Europe, clinical trials are underway for a medicated chewing gum with THC and CBD - to be used in pain management as well as for muscular spasticity in MS patients. "
When asked why chewing gum is a better delivery method for medicines, George E. Anastassov, MD, DDS, MBA and CEO of AXIM Biotech states, "Cannabinoids enter the blood stream directly through the thin oro-pharyngeal mucosa thus bypassing the GI / liver (first pass) of metabolism. Thus, chewing gum provides improved bioavailability and better dosing control. "
An industry leader and innovator, CanChew ®, was featured in Healthy Living Magazine's December issue and also recognized by the HealthyLivinGFoundation and honored with its Triple Leaf Award. CanChew® has been seen in and on:
Healthy Living Magazine


Photo Release -- Patent for World’s First Cannabinoid Release Gum Awarded to Medical Marijuana, Inc.’s Joint Venture Partner -- CanChew Biotechnologies, LLC

March 16-19: ASD – Las Vegas
Continuing the Company's community outreach efforts, the Company donated to MyCompassion.org , and efforts to create awareness of CBD-rich hemp oil expanded throughout the Midwest in March. In addition, HempMedsPX ™ supported AutismOne 's global annual conference during which AutismOne promoted HempMedsPX ™ via multiple radio broadcasts on VoiceAmerica. Medical Marijuana Inc. 's subsidiary Wellness Managed Services launched a joint venture with MPS Security under the brand MPS International ( MPSI ) on January 1, 2014. Operational highlights from Q1 include the following:
MPSI acquired a $250,000 (annual revenue expectation) security account for the Denver Mart in Denver, CO
Began providing security to four dispensaries and retail marijuana stores
Purchased two armored trucks for the Denver location
Hired three new representatives: Two in Colorado and one in Washington
Q1 CBD-rich hemp oil product sales totaled approximately $45,000
In addition to these highlights, MPSI expanded their service offerings to include security consultative services. CanChew Biotechnologies
Sales of CanChew gum for Q1 were $47,730, down from $57,620 in Q4. The reason for the decrease in sales was due to a transition period from HempMedsPX ™ handing all marketing and sales over to CanChew 's internal team, which is also transitioning to a different approach. CanChew 's new strategy involves direct-to-consumer television and advertising, the company has been evaluating several different advertising and media partners for those direct-to-consumer campaigns. MedChewRX , a cannabis-based THC/CBD pharmaceutical drug, made tremendous progress with its clinical trials developed in Europe this year. A more detailed update is expected from CanChew Biotechnologies in Q3 or Q4, depending on continued clinical progress. In addition, CanChew Biotech has been seeking international product registration and approvals to open up additional international markets for their product. Medical Marijuana Inc . and Dixie Holdings, the owner of Dixie Elixirs and Edibles , one of America's first revolutionaries in cannabis-infused edibles, topicals and tinctures, agreed to settle a year-old dispute and execute a mutually beneficial Asset Purchase and Settlement Agreement. While financial terms of the settlement were not disclosed, the core elements were as follows:
Dixie Holdings (DH) agreed to sell its interest in Red Dice Holdings ( RDH ) to Medical Marijuana Inc . ( MJNA );
DH also agreed to purchase its brand and all intellectual property from RDH pertaining to Dixie Elixirs and Edibles, enabling DH to develop and expand its family of THC-infused products, and;
As part of the sale of RDH, MJNA will own the brand and IP specific to  Dixie Botanicals , allowing it to focus that brand specifically on hemp-derived CBD-based products. A statement from  MJNA . Medical Marijuana Inc.  is extremely pleased to announce a Q1 performance that has exceeded expectations, and we apologize for the delay in releasing this report. Due to restructuring, preparing for relocation to new offices and acquisition of 100% of Red Dice Holdings, the release of Q1 financials was, unfortunately, delayed. Investors can rest assured that Q2 financials will be released on time. The Company is incredibly proud of the success of HempMedsPX ™ through its strategic partnerships, public relations and marketing endeavors; investors can look forward to continued success in 2014. This subsidiary has spearheaded the Company's objectives and vision since its inception, and continues to be the driving force behind the extraordinary growth of the MJNA family of companies. We are committed to growing our contributions/sponsorships so that we may give back both to the local community and to those who benefit the most from our products. Everyone at MJNA and HempMedsPX ™ feel compelled to make a difference in the world, and are honored that we have been afforded the opportunity to do so. We couldn't be more proud of the diverse and dynamic group of people we have assembled to not only develop and market industry-leading products and services, but also to bring the greater possibilities of hemp and CBD-rich hemp oil to the mainstream. We continue to seek qualified and driven individuals for the Company's rapid expansion, and ask that anyone who is interested in being part of an established company in a cutting-edge industry to submit their resume to HR@hempmedspx.com . About Medical Marijuana Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For more information, please visit the company's website at: www.MedicalMarijuanaInc.com
About HempMedsPX
HempMedsPX ™ offers mainstream marketing, sales, customer service, and logistics for the cannabis industry. HempMedsPX ™ is a corporate portfolio company of  Medical Marijuana, Inc.  (OTC Pink: MJNA) and the Company's exclusive master distributor and contracted marketing company. In addition to handling sales and distribution,  HempMedsPX ™ is the communication hub for the Medical Marijuana Inc. portfolio of companies. About CanChew Biotechnologies
CanChew Biotechnologies focuses on the treatment of pain and other medical disorders with the application of chewing gum-based cannabis/cannabinoid medical products as well as food and nutraceutical products for general well-being. The company is focused on the R&D and execution of their clinical development plan and potential out-licensing of their technology. Clinical development focuses on the R&D of the formulation, production and the development of chewing gum-based products for the treatment of conditions like pain, nausea and vomiting, anorexia, spasticity and various other medical issues. For more information on the company, visit CanChewBiotech.com . About Wellness Managed Services
Wellness Managed Services provides management support and services to cooperatives, collectives, health and wellness facilities, and medical clinics throughout North America. The services offered range from practice management to product distribution. Our mission is to provide a comprehensive array of clinically supporting health and wellness products and services which will attract patients while providing for a fully operational, profitable enterprise. We seek to provide facilities and patients alike with the latest in quality products and support services that will serve the health and wellness community. For more info,  click here . About MPSI:
MPS International ( MPSI ) is a consulting firm that provides security consultative services to business and individuals in the legal cannabis industry. When security officers are needed, MPSI contracts exclusively with MPS Security to provide uniformed security management and officers. MPSI was created as a specialized division of MPS Security. With over 46 years of experience providing professional security services, MPS Security is uniquely qualified to bring high quality security management and security solutions to the new and growing cannabis industry. Our professional experience and qualifications are helping to legitimize the expanding cannabis industry by reducing crime and assisting legal businesses and individuals to operate in accordance with all federal, state and local laws and regulations. For more details visit www.Security-MPSI.com , email security@security-mpsi.com or call (866) 678-4408. About Red Dice Holdings
Red Dice Holdings, LLC ("Red Dice") is the owner of the Dixie Brand of products including Dixie Elixirs. The company has over 70 unique consumer products and is one of the most recognizable cannabis and hemp brands in the world. For more information on Red Dice Holdings,  click here . FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein. LEGAL DISCLOSURE
Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The Company does grow, sell and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil. For further information, please contact:Investor Relations contact:Perry ColemanMedical Marijuana, Inc.P. 443-453-5088Public Relations contact:Andrew HardDirector of PR, HempMedsP. 858-380-5478Corporate contact:Medical Marijuana, Inc.Toll Free: 888-OTC-MJNA (888-682-6562) www.medicalmarijuanainc.com www.facebook.com/mjnainc
Related Articles
other press releases by Medical Marijuana Inc


Medical Marijuana Inc. Announces First Quarter 2014 Shareholders Report: Product Sales Increase More Than 100% Quarter Over Quarter

Medical Marijuana (“MJNA") is a publicly held company vested in the medical marijuana and industrial hemp markets. The company is comprised of a diversified portfolio of products, services, technology and businesses solely focused on the cannabis and hemp industries.

Medical Marijuana

Dr. Titus continues , `` Further on the medical side , the U.S. Patent 9023322 will allow for CanChew Biotechnologies , LLC , with its relationship with AXIM Biotechnologies , Inc. to develop their MedChew RX ™ plans further .

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Cannabis

Corporate Majority

A company that produces marijuana chewing gum

Date	6/5/2012
Round	Corporate Majority
Amount
Investors	Medical Marijuana
Valuation
Revenue	0 FY undefined
Sources	1

First funding	6/5/2012
Last Funding	6/5/2012
Investor	Medical Marijuana
Rounds	1 Corporate Majority
Board Seats
Type	Corporation
Location

Wells Fargo Success Story

Professional Services

Platform Overview

CanChew Biotechnologies

Investors Count

Funding, Valuation & Revenue

This profile has not been claimed.

CanChew Biotechnologies Investors

Discover the right solution for your team